NCT07323095

Evaluate the Efficacy and Safety of ABP-671 in Subjects With Chronic Kidney Disease and Hyperuricaemia

A Phase 2, International, Multicenter, Randomized, Double-blind, Parallel-group Trial to Evaluate the Efficacy and Safety of ABP-671 in Subjects With Chronic Kidney Disease and Hyperuricaemia

• Status: Not Yet Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 75 (estimated)
• Sponsor: Atom Therapeutics Co., Ltd · Industry
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

This is a phase 2, international, multicenter, randomized, double blind, parallel group trial to evaluate the efficacy and safety of ABP-671 in subjects with CKD and hyperuricaemia, to preliminarily evaluate the efficacy of ABP-671 in the treatment of subjects with CKD and hyperuricemia, primary Efficacy Endpoint is change in UACR from baseline to Week 28

Conditions

• Chronic Kidney Disease

Interventions

Type	Name	Description
DRUG	ABP-671 plus febuxostat Group 1	ABP-671 Dose 1 + Febuxostat Dose 1-tablets(PO)
DRUG	ABP-671 plus febuxostat Group 2	ABP-671 Dose 2 + Febuxostat Dose 2-tablets(PO)
DRUG	ABP-671 Group	ABP-671 Dose 2 + Febuxostat placebo-tablets(PO)

Timeline

• Start date: 2026-02-01
• Primary completion: 2027-10-31
• Completion: 2028-01-31
• First posted: 2026-01-07
• Last updated: 2026-01-07

Locations

8 sites across 2 countries: Australia, China